Evidence map›Paper›PMID 42410699›Full record

ArticleJournal of cellular and molecular medicine2026

circFOXP1 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Regulating EREG/MAPK/ERK Axis.

Leyi Huang, Dan Su, Rihua He, Bingzheng Zhong, Qiang Wang, Fuxu Feng, Jingwen Li, Jie Cao, Quanbo Zhou, Xiaofeng Guo

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Leyi HuangDepartment of Pancreas Center, Guangdong Institute of Cardiovascular Diseases, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
Dan SuDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Rihua HeDepartment of Pancreas Center, Guangdong Institute of Cardiovascular Diseases, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
Bingzheng ZhongDepartment of Gastrointestinal, Hernia, and Abdominal Wall Surgery, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, People's Republic of China.
Qiang WangDepartment of Gastrointestinal, Hernia, and Abdominal Wall Surgery, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, People's Republic of China.
Fuxu FengZhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
Jingwen LiZhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
Jie CaoDepartment of Gastrointestinal, Hernia, and Abdominal Wall Surgery, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, People's Republic of China.
Quanbo ZhouDepartment of Pancreas Center, Guangdong Institute of Cardiovascular Diseases, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
Xiaofeng GuoDepartment of Gastrointestinal, Hernia, and Abdominal Wall Surgery, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, People's Republic of China.ORCID 0000-0003-0650-4800

Funding

Guangzhou High-level Key Clinical Specialty Construction ProjectNational Natural Science Foundation of China 82173236National Natural Science Foundation of China 82203526National Natural Science Foundation of China 82472893Natural Science Foundation of Guangdong Province, China 2022A1515220219Science and Technology Projects in Guangzhou 202201010031Young Talent Support Project of Guangzhou Association for Science and Technology QT2024-036
6 · The paper itself

Abstract

Circular RNAs (circRNAs) are indispensable for triggering pancreatic ductal adenocarcinoma (PDAC) progression. However, the specific biological processes and mechanisms by which circRNAs influence PDAC remain largely unknown. Here, we reported that circFOXP1 is a critical promoter of PDAC progression, exhibiting marked upregulation in patient tumour tissues that correlates with advanced TNM stage and poor prognosis. Functional studies demonstrate that circFOXP1 knockdown significantly suppresses PDAC cell proliferation, migration, and invasion in vitro and in vivo. Mechanistically, circFOXP1 acts as a molecular sponge for miR-320b, leading to the upregulation of epidermal growth factor receptor (EGFR) ligand Epiregulin (EREG) and the subsequent activation of the MAPK/ERK signalling pathway, which is crucial for maintaining the aggressive phenotype of PDAC. The blockade of EREG using neutralizing antibodies in vivo substantially abrogates circFOXP1-induced tumorigenesis. Our findings underscore the potential of circFOXP1 as a novel biomarker and propose a novel therapeutic target to improve survival in PDAC patients.

Indexed as

Carcinoma, Pancreatic DuctalEpiregulinForkhead Transcription FactorsMAP Kinase Signaling SystemPancreatic NeoplasmsRepressor ProteinsRNA, CircularAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleEpiregulinForkhead Transcription FactorsFOXP1 protein, humanMicroRNAsRepressor ProteinsRNA, CircularcircFOXP1epiregulinmiR‐320bpancreatic ductal adenocarcinoma

Identifiers

PMID42410699
PMCPMC13337542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.